Three New Treatments Bring Good News for People with Crohn's
There have been several recent advances in how physicians treat inflammatory bowel disease (IBD). These treatment options have primarily focused on developing biological agents (e.g., antisense oligonucleotides, monoclonal antibodies, and recombinant peptides or proteins) that target the neutralization of specific pro-inflammatory proteins. Monoclonal antibodies that target tumor necrosis factor (TNF) have been found to be especially effective in the treatment of Crohn's disease. The anti-TNF agents range from the human IgG1 anti-TNF-alpha monoclonal antibody, adalimumab to the chimeric monoclonal antibody, infliximab.
The anti-TNF agents have been found to be so effective that they actually reset the acceptable level for response to treatment in Crohn's disease.